Monday, September 08, 2025 3:49:16 PM
hankmanhub,
Some of the same language used in this article comes straight from the what NWBO puts in their Qs so from what you are saying one might conclude that every Q is a soft bash even if that language is not the focus of the company; ). This may be boilerplate stuff but that is what you put in writing to protect against withholding known risks from being announced.
Like I said before, this article offers the opportunity side with the risk side and stays relatively short. This is probably to keep reader attention or because the writer has no depth of understanding there either. Because of this the article misses the opportunity to expand on the expected success of this platform because of the science. The writer could have also mentioned the NHS reclassification to cancer indication from GBM on their high priced medicines list and a few other things that point to eventual success but this does not address the time frame issue for return on investment even if the issue about the treatment working is cleared up by the preponderance of evidence.
I believe the term “niche innovator” that was used refers to dendritic cell therapy itself, not the number of indications it will likely treat. Cell therapy is not widely in circulation now for all types of cancer treatment and beyond but as those of us who see this from the science side see it that is about to change in a big way. This writer does not approach this from that angle and probably stays in their lane by sticking to the layman’s view and concerns. Those concerns are focused on the treatment working and the company making money now or soon so that any investment will provide a reasonable chance for a decent return in a reasonable amount of time. Current long time longs have held way beyond what most investors would consider a reasonable amount of time for a good return but that is because they (we) expect way outsized returns. However, if “soon” is not well defined then “soon” remains a legitimate concern for new investors. For us old timers who have a different view of “soon” I can see how the risks mentioned would look like a soft bash; ). Best wishes.
Some of the same language used in this article comes straight from the what NWBO puts in their Qs so from what you are saying one might conclude that every Q is a soft bash even if that language is not the focus of the company; ). This may be boilerplate stuff but that is what you put in writing to protect against withholding known risks from being announced.
Like I said before, this article offers the opportunity side with the risk side and stays relatively short. This is probably to keep reader attention or because the writer has no depth of understanding there either. Because of this the article misses the opportunity to expand on the expected success of this platform because of the science. The writer could have also mentioned the NHS reclassification to cancer indication from GBM on their high priced medicines list and a few other things that point to eventual success but this does not address the time frame issue for return on investment even if the issue about the treatment working is cleared up by the preponderance of evidence.
I believe the term “niche innovator” that was used refers to dendritic cell therapy itself, not the number of indications it will likely treat. Cell therapy is not widely in circulation now for all types of cancer treatment and beyond but as those of us who see this from the science side see it that is about to change in a big way. This writer does not approach this from that angle and probably stays in their lane by sticking to the layman’s view and concerns. Those concerns are focused on the treatment working and the company making money now or soon so that any investment will provide a reasonable chance for a decent return in a reasonable amount of time. Current long time longs have held way beyond what most investors would consider a reasonable amount of time for a good return but that is because they (we) expect way outsized returns. However, if “soon” is not well defined then “soon” remains a legitimate concern for new investors. For us old timers who have a different view of “soon” I can see how the risks mentioned would look like a soft bash; ). Best wishes.
Recent NWBO News
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
